Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

actinium Ac 225 rosopatamab tetraxetan

A radioimmunoconjugate consisting of a humanized monoclonal antibody directed against prostate specific membrane antigen (PSMA) labeled with the alpha particle-emitting radioisotope actinium Ac-225, with potential antineoplastic activity. Upon administration, actinium Ac 225 rosopatamab tetraxetan binds to the extracellular domain of PSMA with high affinity, thereby delivering alpha radiation to PSMA expressing cells. PSMA, a type II membrane protein expressed in all types of prostatic tissues, is often overexpressed in tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Ac 225 MOAB J591
Ac 225 monoclonal antibody J591
actinium Ac-225 anti-prostate-specific membrane antigen monoclonal antibody J591
actinium Ac-225 anti-PSMA monoclonal antibody J591
Abbreviation:225Ac-J591
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search